Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
Crossref DOI link: https://doi.org/10.1186/s12885-023-10959-3
Published Online: 2023-05-19
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Liu, Wenjie
Huo, Gengwei
Chen, Peng
Text and Data Mining valid from 2023-05-19
Version of Record valid from 2023-05-19
Article History
Received: 2 January 2023
Accepted: 13 May 2023
First Online: 19 May 2023
Declarations
:
: Not applicable.
: The authors declare no competing interests.